Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385584376> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4385584376 endingPage "iii14" @default.
- W4385584376 startingPage "iii14" @default.
- W4385584376 abstract "Abstract OBJECTIVES Leptomeningeal metastases (LM) are an increasing complication of metastatic cancer with limited treatment options and poor survival. 186RNL is BMEDA-chelated 186Re encapsulated in nanoliposomes. 186Re’s ~2 mm beta emission path length provides direct delivery of radiation therapy while sparing surrounding healthy tissue. A Phase I dose escalation safety and efficacy study (ReSPECT-LM, NCT05034497) is current enrolling. METHODS ReSPECT-LM is a multi-center, sequential cohort, open-label, dose-escalation, Phase 1/2a clinical trial in adults evaluating the safety, tolerability, and activity of a single dose of 186RNL given via Ommaya reservoir. The primary objectives are maximum tolerated dose, safety, progression, and survival. Using a modified 3x3 Fibonacci design, increasing doses were administered in 5 mL followed by whole body planar and SPECT/CT imaging for dosimetry and distribution. CSF tumor cell count/mL using microfluidic chamber assay was assessed up to 56 days. RESULTS A total of 7 LM patients have been treated (3 male, 4 female) with metastatic oropharyngeal, breast, and lung cancer. One patient was treated twice (retreatment). 186RNL showed prompt, complete distribution throughout the CSF with durable retention in the subarachnoid space and leptomeninges. Absorbed doses ≥20 Gy to the ventricles and cranial subarachnoid spaces were measured. In patients positive for CSF tumor cells, a decrease in counts ranging from 50-92% was observed. Six patients remain alive, while 1 patient has died due to primary tumor progression. No patients had treatment related adverse events (AEs) greater than Grade 1, and the most common AE was headache. CONCLUSION Preliminary, interim results of this ongoing study showed that a single treatment with 186RNL delivered by an intraventricular catheter is well tolerated, without dose limiting toxicity and with decreased CSF tumor cell counts durable through at least 30 days. Enrollment and dose escalation is continuing, and repeated dosing will be further explored." @default.
- W4385584376 created "2023-08-05" @default.
- W4385584376 creator A5000069746 @default.
- W4385584376 creator A5001638504 @default.
- W4385584376 creator A5019498881 @default.
- W4385584376 creator A5034127714 @default.
- W4385584376 creator A5035871654 @default.
- W4385584376 creator A5048202536 @default.
- W4385584376 creator A5068799740 @default.
- W4385584376 creator A5073397833 @default.
- W4385584376 creator A5076877923 @default.
- W4385584376 creator A5083922162 @default.
- W4385584376 date "2023-08-01" @default.
- W4385584376 modified "2023-09-24" @default.
- W4385584376 title "LMAP-21 PRELIMINARY CLINICAL DATA IN THE PHASE 1/2A DOSE ESCALATION TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN LEPTOMENINGEAL METASTASES (LM): THE RESPECT-LM TRIAL" @default.
- W4385584376 doi "https://doi.org/10.1093/noajnl/vdad070.052" @default.
- W4385584376 hasPublicationYear "2023" @default.
- W4385584376 type Work @default.
- W4385584376 citedByCount "0" @default.
- W4385584376 crossrefType "journal-article" @default.
- W4385584376 hasAuthorship W4385584376A5000069746 @default.
- W4385584376 hasAuthorship W4385584376A5001638504 @default.
- W4385584376 hasAuthorship W4385584376A5019498881 @default.
- W4385584376 hasAuthorship W4385584376A5034127714 @default.
- W4385584376 hasAuthorship W4385584376A5035871654 @default.
- W4385584376 hasAuthorship W4385584376A5048202536 @default.
- W4385584376 hasAuthorship W4385584376A5068799740 @default.
- W4385584376 hasAuthorship W4385584376A5073397833 @default.
- W4385584376 hasAuthorship W4385584376A5076877923 @default.
- W4385584376 hasAuthorship W4385584376A5083922162 @default.
- W4385584376 hasBestOaLocation W43855843761 @default.
- W4385584376 hasConcept C126322002 @default.
- W4385584376 hasConcept C143998085 @default.
- W4385584376 hasConcept C197934379 @default.
- W4385584376 hasConcept C2776694085 @default.
- W4385584376 hasConcept C2778375690 @default.
- W4385584376 hasConcept C2779651940 @default.
- W4385584376 hasConcept C2780813603 @default.
- W4385584376 hasConcept C2781393001 @default.
- W4385584376 hasConcept C2989005 @default.
- W4385584376 hasConcept C535046627 @default.
- W4385584376 hasConcept C71924100 @default.
- W4385584376 hasConceptScore W4385584376C126322002 @default.
- W4385584376 hasConceptScore W4385584376C143998085 @default.
- W4385584376 hasConceptScore W4385584376C197934379 @default.
- W4385584376 hasConceptScore W4385584376C2776694085 @default.
- W4385584376 hasConceptScore W4385584376C2778375690 @default.
- W4385584376 hasConceptScore W4385584376C2779651940 @default.
- W4385584376 hasConceptScore W4385584376C2780813603 @default.
- W4385584376 hasConceptScore W4385584376C2781393001 @default.
- W4385584376 hasConceptScore W4385584376C2989005 @default.
- W4385584376 hasConceptScore W4385584376C535046627 @default.
- W4385584376 hasConceptScore W4385584376C71924100 @default.
- W4385584376 hasIssue "Supplement_3" @default.
- W4385584376 hasLocation W43855843761 @default.
- W4385584376 hasOpenAccess W4385584376 @default.
- W4385584376 hasPrimaryLocation W43855843761 @default.
- W4385584376 hasRelatedWork W1556562895 @default.
- W4385584376 hasRelatedWork W2057339290 @default.
- W4385584376 hasRelatedWork W2087016115 @default.
- W4385584376 hasRelatedWork W2107697672 @default.
- W4385584376 hasRelatedWork W2160729253 @default.
- W4385584376 hasRelatedWork W2335774562 @default.
- W4385584376 hasRelatedWork W2349164817 @default.
- W4385584376 hasRelatedWork W2363981502 @default.
- W4385584376 hasRelatedWork W3189762672 @default.
- W4385584376 hasRelatedWork W4251165208 @default.
- W4385584376 hasVolume "5" @default.
- W4385584376 isParatext "false" @default.
- W4385584376 isRetracted "false" @default.
- W4385584376 workType "article" @default.